DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Asacol (Mesalamine) - Published Studies

 
 



Asacol Related Published Studies

Well-designed clinical trials related to Asacol (Mesalamine)

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. [2011.02]

A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. [2011.02]

Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. [2010.11]

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. [2010.10]

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. [2010.04]

Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. [2010.02]

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. [2010]

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. [2009.12]

Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. [2009.08]

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. [2009.07]

Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial. [2009.05]

Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. [2008.12]

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. [2005.11]

Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. [2005.07]

Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. [2005.05.01]

Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. [2005.04]

Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. [2004.09]

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. [2004.09]

Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. [2004.05.15]

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. [2003.07.24]

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. [2003.05]

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. [2003.03]

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. [2003.01]

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. [2002.12]

A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. [2002.06]

Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. [2002.05]

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. [2000.07]

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. [2000.02]

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. [1999.03]

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. [1998.08.06]

Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. [1998.06]

Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. [1998.05]

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. [1998.01]

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. [1997.10]

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. [1997.04]

A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. [1996.07]

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. [1996.03]

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. [1995.08]

Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. [1995.05]

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. [1995.02]

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. [1995.02]

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. [1994.12]

Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. [1994.02]

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). [1994.02]

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. [1993.08]

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. [1993.05]

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) [1993.02]

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. [1992.08]

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. [1991.09.01]

Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. [1990.11]

Well-designed clinical trials possibly related to Asacol (Mesalamine)

Abatacept for Crohn's disease and ulcerative colitis. [2012]

Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. [2012]

Drug development in inflammatory bowel disease: The role of the FDA. [2011.12]

Individually tailored treatment of medication nonadherence. [2011.10]

Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: A double-blinded and randomized study. [2011.09.06]

The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis. [2011.09]

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. [2011.05]

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. [2011.04]

Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. [2011.04]

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011.03]

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. [2011.02]

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. [2011.01]

Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. [2011.01]

Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. [2011]

Curcumin for inflammatory bowel disease: a review of human studies. [2011]

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. [2011]

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011]

Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. [2011]

Aminosalicylates for induction of remission or response in Crohn's disease. [2010.12.08]

E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. [2010.12]

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. [2010.10]

Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. [2010.08]

Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. [2010.08]

Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. [2010.08]

Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. [2010.07]

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. [2010.06]

Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. [2010.06]

Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. [2010.04]

Efficacy of 5-ASA in the treatment of colonic diverticular disease. [2010.02]

Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. [2009.11]

Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. [2009.11]

In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. [2009.09.15]

[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease] [2009.09]

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. [2009.08]

The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. [2009.07]

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. [2009.06]

Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. [2009.05]

Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. [2009.03]

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. [2009.02]

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. [2009.02]

Budesonide for maintenance of remission in Crohn's disease. [2009.01.21]

Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. [2009.01]

Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. [2009]

Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. [2008.11]

Budesonide for induction of remission in Crohn's disease. [2008.07.16]

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. [2008.07]

Can 5-aminosalicylic acid suppository decrease the pain after rectal band ligation? [2008.06.14]

Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. [2008.05]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012